Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 2, 2003, Pages 259-266

  Ziemer, L S ^a   Evans, S M ^b   Kachur, A V ^b   Shuman, A L ^b   Cardi, C A ^b   Jenkins, W T ^b   Karp, J S ^b   Alavi, A ^b   Dolbier Jr , W R ^c   Koch, C J ^b  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c University of Florida ^*  (United States)

Author keywords

EF5; Glioma; Hepatoma; Hypoxia; PET

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE F 18; 2 NITROIMIDAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CANCER THERAPY; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG MUSCLE LEVEL; DRUG TISSUE LEVEL; HYPOXIA; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INJECTION; INTERMETHOD COMPARISON; MALE; NON INVASIVE MEASUREMENT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RAT; TUMOR SCINTISCANNING; TUMOR VOLUME; URINARY EXCRETION; VALIDATION PROCESS;

EID: 0038797936     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-1037-5     Document Type: Article

References (49)

1. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56:4509-4515.
2. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56:941-943.
3. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38:285-289.
4. Chapman JD, Baer K, Lee J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res 1983; 43:1523-1528.
5. Lord EM, Harwell L, Koch CJ. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res 1993; 53:5721-5726.
6. Raleigh JA, Miller GG, Franko AJ, Koch CJ, Fuciarelli AF, Kelly DA. Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours. Br J Cancer 1987; 56:395-400.
7. 19F magnetic resonance method for measuring oxygen deficiency in tumors. Magn Reson Med 1991; 22:451-466.
8. Hodgkiss RJ, Jones G, Long A, et al. Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection. Br J Cancer 1991; 63:119-125.
9. Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [F-18]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996; 36:417-428.
10. Rasey JS, Hofstrand PD, Chin LK, Tewson TJ. Characterization of [F-18]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 1999; 40:1072-1079.
11. Rasey JS, Grunbaum Z, Magee S, et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res 1987; 111:292-304.
12. Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992; 33:2133-2137.
13. Yeh SH, Liu RS, Wu LC, et al. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med 1996; 23:1378-1383.
14. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995; 33:391-398.
15. Martin GV, Caldwell JH, Graham MM, et al. Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. J Nucl Med 1992; 33:2202-2208.
16. Okada RD, Johnson G 3rd, Nguyen KN, Edwards B, Archer CM, Kelly JD. Tc-99m-HL91. Effects of low flow and hypoxia on a new ischemia-avid myocardial imaging agent. Circulation 1997; 95:1892-1899.
17. Okada RD, Johnson G 3rd, Nguyen KN, et al. Tc-99m-HL91: "hot spot" detection of ischemic myocardium in vivo by gamma camera imaging. Circulation 1998; 97:2557-2566.
18. Gronroos T, Eskola O, Lehtio K, et al. Pharmacokinetics of [F-18]FETNIM: a potential marker for PET. J Nucl Med 2001; 42:1397-1404.
19. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997; 38:1155-1160.
20. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999; 40:177-183.
21. 123I-iodoazomycin arabinoside: preliminary report of a clinical study. Br J Cancer 1992; 65:90-95.
22. 131I]iodoerythronitroimidazole. J Drug Target 1996; 4:31-39.
23. Groshar D, McEwan AJ, Parliament MB, et al. Imaging tumor hypoxia and tumor perfusion. J Nucl Med 1993; 34:885-888.
24. Linder KE, Chan YW, Cyr JE, Malley MF, Nowotnik DP, Nunn AD. TcO(PnAO-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis, characterization, and xanthine oxidase-catalyzed reduction. J Med Chem 1994; 37:9-17.
25. Ballinger JR, Kee JW, Rauth AM. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. J Nucl Med 1996; 37:1023-1031.
26. Melo T, Duncan J, Ballinger JR, Rauth AM. BRU59-21, a second-generation Tc-99m-labeled 2-nitroimidazole for imaging hypoxia in tumors. J Nucl Med 2000; 41:169-176.
27. Cook GJ, Houston S, Barrington SF, Fogelman I. Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG. J Nucl Med 1998; 39:99-103.
28. Evans SM, Joiner B, Jenkins WT, Laughlin KM, Lord EM, Koch CJ. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. Br J Cancer 1995; 72:875-882.
29. Evans SM, Jenkins WT, Joiner B, Lord EM, Koch CJ. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res 1996; 56:405-411.
30. Laughlin KM, Evans SM, Jenkins WT, et al. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors. J Pharmacol Exp Ther 1996; 277:1049-1057.
31. Koch CJ, Hahn SM, Rockwell K Jr, Covey JM, McKenna WG, Evans SM. Pharmacokinetics of EF5 [2-(2-nitro-1-Himidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles. Cancer Chemother Pharmacol 2001; 48:177-187.
32. Kachur AV, Dolbier WR Jr, Evans SM, et al. Synthesis of new hypoxia markers EF1 and [F-18]-EF1. Appl Radiat Isot 1999; 51:643-650.
33. Evans SM, Kachur AV, Shiue CY, et al. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [F-18]EF1. J Nucl Med 2000; 41:327-336.
34. Josse O, Labar D, Georges B, Gregoire V, Marchand-Brynaert J. Synthesis of [F-18]-labeled EF3 [2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide], a marker for PET detection of hypoxia. Bioorg Med Chem 2001; 9:665-675.
35. Dolbier WR Jr, Li AR, Koch CJ, Shiue CY, Kachur AV. [F-18]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. Appl Radiat Isot 2001; 54:73-80.
36. Karp JS, Freifelder R, Geagan MJ, et al. Three-dimensional imaging characteristics of the HEAD PENN-PET scanner. J Nucl Med 1997; 38:636-643.
37. Koch CJ, Evans SM, Lord EM. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br J Cancer 1995; 72:869-874.
38. Evans SM, Hahn SM, Magarelli DP, Koch CJ. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am J Clin Oncol 2001; 24:467-472.
39. Evans SM, Hahn SM, Magarelli DP, et al. Hypoxia in human intraperitoneal and extremity sarcomas. Int J Radiat Oncol Biol Phys 2001; 49:587-596.
40. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992; 22:199-212.
41. Graham MM, Peterson LM, Link JM, et al. Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. J Nucl Med 1997; 38:1631-1636.
42. Wiebe LI, Stypinski D. Pharmacokinetics of SPECT radiopharmaceuticals for imaging hypoxic tissues. Q J Nucl Med 1996; 40:270-284.
43. Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998; 46:229-237.
44. Chapman JD, Zanzonico P, Ling CC. On measuring hypoxia in individual tumors with radiolabeled agents. J Nucl Med 2001; 42:1653-1655.
45. 123I-IAZA in healthy volunteers. Nucl Med Commun 1999; 20:559-567.
46. Minn H, Clavo AC, Wahl RL. Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol 1996; 23:941-946.
47. Kavanagh MC, Tsang V, Chow S, et al. A comparison in individual murine tumors of techniques for measuring oxygen levels. Int J Radiat Oncol Biol Phys 1999; 44:1137-1146.
48. Lee J, Siemann DW, Koch CJ, Lord EM. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts. Int J Cancer 1996; 67:372-378.
49. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58:1408-1416.